Huntington National Bank Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Huntington National Bank boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 789 shares of the biopharmaceutical company’s stock after buying an additional 75 shares during the period. Huntington National Bank’s holdings in Regeneron Pharmaceuticals were worth $381,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $6,829,000. FMR LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 47.2% during the 2nd quarter. FMR LLC now owns 12,463,480 shares of the biopharmaceutical company’s stock valued at $7,772,849,000 after purchasing an additional 3,999,170 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Regeneron Pharmaceuticals by 18.0% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 592,199 shares of the biopharmaceutical company’s stock valued at $331,501,000 after acquiring an additional 90,142 shares during the period. Jupiter Asset Management Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $8,378,000. Finally, Sei Investments Co. increased its position in shares of Regeneron Pharmaceuticals by 31.6% in the 3rd quarter. Sei Investments Co. now owns 32,000 shares of the biopharmaceutical company’s stock valued at $18,033,000 after acquiring an additional 7,676 shares during the period. Hedge funds and other institutional investors own 85.89% of the company’s stock.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald raised Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $690.00 target price on the stock in a research report on Monday, October 5th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 1st. FIX raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and cut their target price for the company from $635.00 to $575.00 in a research report on Friday, January 8th. ValuEngine downgraded Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 10th. Finally, Truist increased their price target on Regeneron Pharmaceuticals from $750.00 to $770.00 in a research report on Friday, November 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $619.33.

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $548.54, for a total value of $54,854.00. Following the transaction, the director now directly owns 27,323 shares of the company’s stock, valued at approximately $14,987,758.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 11.84% of the company’s stock.

REGN stock opened at $511.90 on Thursday. The company’s 50-day simple moving average is $493.59 and its 200-day simple moving average is $567.31. The company has a quick ratio of 1.68, a current ratio of 2.12 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $328.13 and a 52-week high of $664.64. The firm has a market cap of $54.62 billion, a P/E ratio of 19.82, a PEG ratio of 1.80 and a beta of 0.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $8.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.52 by ($1.16). Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The firm had revenue of $2.29 billion for the quarter, compared to analysts’ expectations of $2.09 billion. During the same period in the previous year, the company earned $6.67 earnings per share. The company’s revenue was up 31.6% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 28.16 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: What is the price-sales ratio?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.